📊 SCYX Key Takeaways
Is Scynexis Inc. (SCYX) a Good Investment?
SCYNEXIS exhibits exceptional revenue growth (+449.9% YoY) but this growth quality is severely compromised by a near-zero 0.3% gross margin, substantial operating losses (-$16.1M), and significant negative operating cash flow (-$5.3M). The company is burning cash despite topline growth, with limited runway given $34.6M debt obligations and an inability to cover interest expenses from operations.
Why Buy Scynexis Inc. Stock? SCYX Key Strengths
- Exceptional revenue growth of 449.9% YoY demonstrates strong market demand or successful product launch
- Strong liquidity position with 7.04x current ratio and $21.3M cash enabling operational flexibility
- Moderate leverage at 0.70x Debt/Equity provides some financial stability and borrowing capacity
SCYX Stock Risks: Scynexis Inc. Investment Risks
- Critically low gross margin of 0.3% indicates minimal profitability per revenue dollar and potential unsustainable business model
- Negative operating cash flow of -$5.3M despite high revenue suggests poor unit economics and cash burn incompatible with long-term viability
- Operating losses of -$16.1M combined with -39.9x interest coverage ratio indicates inability to service debt obligations from operations
- Estimated cash runway of 4 quarters at current burn rate creates significant refinancing risk
- Pharmaceutical sector execution risk with no margin of safety given current financial structure
Key Metrics to Watch
- Gross margin trend - must improve substantially from current 0.3% level
- Operating cash flow - critical indicator of whether growth translates to sustainable business
- Cash balance depletion rate - monitor runway to determine refinancing needs
- Operating loss trajectory - path to profitability is essential for viability
Scynexis Inc. (SCYX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.04x current ratio provides a solid financial cushion.
SCYX Profit Margin, ROE & Profitability Analysis
SCYX vs Healthcare Sector: How Scynexis Inc. Compares
How Scynexis Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scynexis Inc. Stock Overvalued? SCYX Valuation Analysis 2026
Based on fundamental analysis, Scynexis Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scynexis Inc. Balance Sheet: SCYX Debt, Cash & Liquidity
SCYX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scynexis Inc.'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.44 indicates the company is currently unprofitable.
SCYX Revenue Growth, EPS Growth & YoY Performance
SCYX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $334.0K | -$2.8M | $-0.06 |
| Q2 2025 | $736.0K | -$6.9M | $-0.14 |
| Q1 2025 | $257.0K | $411.0K | $0.01 |
| Q3 2024 | $660.0K | -$1.8M | $-0.04 |
| Q2 2024 | $736.0K | -$14.0M | $-0.29 |
| Q1 2024 | $1.1M | $411.0K | $0.01 |
| Q3 2023 | $1.6M | -$1.8M | $-0.04 |
| Q2 2023 | $1.3M | -$13.3M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scynexis Inc. Dividends, Buybacks & Capital Allocation
SCYX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scynexis Inc. (CIK: 0001178253)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SCYX
What is the AI rating for SCYX?
Scynexis Inc. (SCYX) has an AI rating of SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SCYX's key strengths?
Claude: Exceptional revenue growth of 449.9% YoY demonstrates strong market demand or successful product launch. Strong liquidity position with 7.04x current ratio and $21.3M cash enabling operational flexibility.
What are the risks of investing in SCYX?
Claude: Critically low gross margin of 0.3% indicates minimal profitability per revenue dollar and potential unsustainable business model. Negative operating cash flow of -$5.3M despite high revenue suggests poor unit economics and cash burn incompatible with long-term viability.
What is SCYX's revenue and growth?
Scynexis Inc. reported revenue of $20.6M.
Does SCYX pay dividends?
Scynexis Inc. does not currently pay dividends.
Where can I find SCYX SEC filings?
Official SEC filings for Scynexis Inc. (CIK: 0001178253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SCYX's EPS?
Scynexis Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SCYX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Scynexis Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SCYX stock overvalued or undervalued?
Valuation metrics for SCYX: ROE of -17.4% (sector avg: 15%), net margin of -41.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SCYX stock in 2026?
Our dual AI analysis gives Scynexis Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SCYX's free cash flow?
Scynexis Inc.'s operating cash flow is $-5.3M, with capital expenditures of $0.0. FCF margin is -25.6%.
How does SCYX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -41.8% (avg: 12%), ROE -17.4% (avg: 15%), current ratio 7.04 (avg: 2).